What are biosimilars and how do they impact pharmaceutical companies?

Biosimilars are biological products highly similar to an already approved biological medicine. They are not exact generics but aim to provide similar efficacy and safety. For companies like Amgen Inc., biosimilar competition can erode sales of key blockbuster drugs, creating pressure on revenue and market share, necessitating strategic responses such as pipeline diversification and cost management.

What is meant by a "robust oncology portfolio" and why is it important for a biopharma company?

A "robust oncology portfolio" refers to a strong and diverse collection of cancer treatments. For a company like Amgen Inc., this signifies multiple successful drugs, such as Lumakras, addressing various cancer types. It is crucial for sustained revenue growth, establishing a strong market presence, and reducing reliance on any single product, thereby enhancing long-term stability.

How does the Price-to-Earnings (P/E) ratio help assess a company's valuation?

The P/E ratio is a valuation metric comparing a company's share price to its earnings per share. It indicates how much investors are willing to pay for each pound of a company's earnings. A lower P/E, such as Gilead Sciences Inc.'s 14.19, might suggest an attractive valuation, potentially indicating the stock is undervalued compared to its industry peers, assuming consistent earnings.

What are the implications of "biosimilar competition" for investors?

For investors, biosimilar competition typically implies a threat to the market exclusivity and revenue streams of established blockbuster drugs. Companies facing this, such as Amgen Inc. with products like Enbrel and Prolia, may experience reduced sales and profitability, potentially impacting dividend growth and overall financial performance. This often necessitates a focus on innovation and new product development.

How do "high R&D expenses" affect a company's financial health and future prospects?

High Research and Development (R&D) expenses, as seen with Amgen Inc.'s obesity drug progress, can initially weigh on a company's profit margins and earnings. However, these investments are vital for driving future growth by developing new drugs and expanding the product pipeline. Successful R&D can lead to lucrative new revenue streams, market leadership, and long-term shareholder value.

Why would an "attractive valuation" be considered a positive for a stock?

An attractive valuation, like Gilead Sciences Inc.'s forward P/E of 14.19 trading at a discount, suggests that the company's shares may be undervalued relative to its earnings potential or compared to competitors. This could appeal to investors looking for growth opportunities at a reasonable price, as the stock might have significant room for appreciation if its performance improves or market sentiment shifts.

What might "insider sales" indicate to potential investors?

Insider sales refer to company executives or directors selling their own shares. While there can be various personal reasons for such transactions, significant or widespread insider selling, as observed with Gilead Sciences Inc., might signal that those closest to the company perceive limited near-term upside or have concerns about its future performance. Investors often monitor these actions closely.

How do "regulatory delays" affect a biotechnology company's market position?

Regulatory delays, such as those impacting Amgen Inc.'s novel assets like MariTide, can significantly affect a biotechnology company's market position. They delay the launch of potentially lucrative products, postponing revenue generation and allowing competitors to advance. Such delays increase uncertainty, can erode investor confidence, and impact market share, making pipeline execution a critical factor for success.

What is the significance of a "dominant franchise" within a specific disease area like HIV?

A dominant franchise, such as Gilead Sciences Inc.'s strong position in the HIV market with products like Yeztugo and Descovy, provides a stable and predictable revenue stream. This leadership establishes the company as a key player in that therapeutic area, offering a competitive advantage, supporting further investment in related research, and enhancing overall market stability and recognition.

How should a beginner interpret the information provided on this comparison page?

Beginners should interpret this page as an educational tool to understand various financial and market aspects of companies like Amgen Inc. and Gilead Sciences Inc. It offers general insights and context for comparing two biotechnology firms. Please remember, this content is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any securities. Always conduct your own comprehensive research before making investment decisions.

Live Report · Updated 12 June 2026

Amgen vs Gilead Sciences

Large biotech company with established medicines and steady dividends vs Pharmaceutical giant with HIV hepatitis and cancer treatments. Which is the better buy for your portfolio in June 2026? Plain-English answer below.

Amgen pioneers biologic therapeutics and biosimilars from a massive internal R&D engine and a late-cycle acquisition strategy anchored by the Horizon Therapeutics deal, while Gilead Sciences dominates HIV and liver disease treatments and has spent years trying to diversify into oncology. Both large-cap biotechs generate prodigious free cash flow and return capital aggressively, yet their pipeline profiles and therapeutic concentrations differ significantly. The Amgen vs Gilead Sciences breakdown shows investors how patent cliff exposure, pipeline depth, and capital allocation choices separate two cash-rich biotech giants navigating the next decade of drug approvals.

Amgen pioneers biologic therapeutics and biosimilars from a massive internal R&D engine and a late-cycle acquisition strategy anchored by the Horizon Therapeutics deal, while Gilead Sciences dominates...

Comparison Snapshot

Key Financial Metrics

AMGN

Metric

GILD

$191.70B

Market Cap

$155.93B

-13.19%

Potential Profit

-26.81%

Hold

Analyst Rating

Buy

Why It’s Moving

Amgen slips as analysts say obesity-drug optimism may already be priced in

Truist cut Amgen to Hold from Buy, signaling that the stock’s recent rally had already captured much of the upside tied to its obesity-drug story.
The firm still raised its price target to $333, but that implies only a small gain from recent trading levels, reinforcing the idea that expectations are now more restrained.
Broader analyst sentiment remains cautious, with consensus views clustering around Hold and some firms flagging downside risk if pipeline momentum or launch assumptions cool.

Sentiment:

🐻Bearish

Gilead is under pressure as analysts flag limited upside and policy risks keep sentiment cautious.

Royal Bank of Canada recently trimmed its price target on Gilead, signaling a more conservative view of near-term upside and reinforcing the market's focus on valuation rather than a fresh growth catalyst.
Consensus analyst estimates still show a modest downside gap from some recent price targets, which suggests investors are increasingly questioning whether the stock can rerate without stronger pipeline or earnings momentum.
In the absence of a major earnings beat or new product update over the last week, GILD is trading more like a defensive pharma name caught in a broader caution wave across the sector.

Sentiment:

🐻Bearish

Amgen slips as analysts say obesity-drug optimism may already be priced in

Truist cut Amgen to Hold from Buy, signaling that the stock’s recent rally had already captured much of the upside tied to its obesity-drug story.
The firm still raised its price target to $333, but that implies only a small gain from recent trading levels, reinforcing the idea that expectations are now more restrained.
Broader analyst sentiment remains cautious, with consensus views clustering around Hold and some firms flagging downside risk if pipeline momentum or launch assumptions cool.

Sentiment:

🐻Bearish

Gilead is under pressure as analysts flag limited upside and policy risks keep sentiment cautious.

Royal Bank of Canada recently trimmed its price target on Gilead, signaling a more conservative view of near-term upside and reinforcing the market's focus on valuation rather than a fresh growth catalyst.
Consensus analyst estimates still show a modest downside gap from some recent price targets, which suggests investors are increasingly questioning whether the stock can rerate without stronger pipeline or earnings momentum.
In the absence of a major earnings beat or new product update over the last week, GILD is trading more like a defensive pharma name caught in a broader caution wave across the sector.

Sentiment:

🐻Bearish

Investment Analysis

Amgen

AMGN

Pros

Amgen maintains a robust oncology portfolio with blockbuster drugs like Lumakras driving consistent revenue growth.
Rare disease franchise, including Tepezza, provides high-margin recurring revenues and shields against generic erosion.
Strong balance sheet supports dividend growth and strategic acquisitions amid pipeline advancements.

Considerations

Biosimilar competition erodes sales of key blockbusters such as Enbrel and Prolia.
High R&D expenses pressure margins despite obesity drug progress in early stages.
Regulatory delays in novel assets like MariTide expose pipeline execution risks.

Gilead Sciences

GILD

Pros

Dominant HIV franchise with Yeztugo launch momentum bolsters market share alongside Descovy's 45% penetration.
Attractive valuation at forward P/E of 14.19 trades at discount to industry peers.
Expanding oncology pipeline nears key regulatory milestones for sustained growth.

Considerations

Upcoming quarterly EPS projected to decline 1.58% year-over-year amid flat revenue.
Recent insider sales signal potential short-term concerns over performance.
Modest consensus price target implies limited near-term upside from current levels.

Related Market Insights

Cancer Therapies: What's Next After 100% Response Rate

Regeneron's 100% response rate signals a new era in cancer treatment. Explore investment opportunities in immuno-oncology & breakthrough therapies with Nemo.